tetano
Editor, Senior Moderator
Obstet Gynecol. 2012 Feb;119(2 Pt 1):306-14.
Cost-benefit analysis of in-hospital influenza vaccination of postpartum women.
Ding Y, Zangwill KM, Hay JW, Allred NJ, Yeh SH.
Source
From the Leonard Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California; UCLA Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California; and the Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
OBJECTIVE:
: To estimate the potential economic benefits associated with hospital-based postpartum influenza vaccination.
METHODS:
: We constructed a decision analysis model to estimate the potential cost benefit of this strategy from both a societal perspective and a third-party perspective. We included a hypothetical cohort of 1.47 million U.S. postpartum women, assuming an influenza season beginning September 1 and ending April 30. Probabilities and costs were derived from published literature, Centers for Disease Control and Prevention data, and expert recommendations. We used one-way and two-way sensitivity analyses. All cost estimates were inflated to year 2010 U.S. dollars and discounted at a 3% annual discount rate.
RESULTS:
: From the societal perceptive, the expected costs per vaccinated and unvaccinated mother were $328.45 and $341.02 respectively, resulting in an expected net benefit of $12.57 per vaccinated mother. The overall savings in the cohort were predicted to range from $3.69 to $14.75 million, depending on the vaccination coverage rate. This strategy would be cost-beneficial, holding all other variables to the base case, if the annual maternal influenza attack rate is more than 2.8%, influenza vaccine efficacy is more than 47%, or if vaccine acquisition and administration cost per dose are less than $32.78. The strategy would not generate net savings from the third-party perspective. Sensitivity analyses were robust, but disease incidence and vaccine efficacy were important drivers.
CONCLUSION:
: Our model suggests that postpartum influenza vaccination is a cost-beneficial approach for prevention of maternal and infantile influenza from a societal perspective.
LEVEL OF EVIDENCE:
: III.
PMID:
22270282
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22270282
Cost-benefit analysis of in-hospital influenza vaccination of postpartum women.
Ding Y, Zangwill KM, Hay JW, Allred NJ, Yeh SH.
Source
From the Leonard Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, California; UCLA Center for Vaccine Research, Los Angeles Biomedical Research Institute at Harbor-UCLA, Torrance, California; and the Centers for Disease Control and Prevention, Atlanta, Georgia.
Abstract
OBJECTIVE:
: To estimate the potential economic benefits associated with hospital-based postpartum influenza vaccination.
METHODS:
: We constructed a decision analysis model to estimate the potential cost benefit of this strategy from both a societal perspective and a third-party perspective. We included a hypothetical cohort of 1.47 million U.S. postpartum women, assuming an influenza season beginning September 1 and ending April 30. Probabilities and costs were derived from published literature, Centers for Disease Control and Prevention data, and expert recommendations. We used one-way and two-way sensitivity analyses. All cost estimates were inflated to year 2010 U.S. dollars and discounted at a 3% annual discount rate.
RESULTS:
: From the societal perceptive, the expected costs per vaccinated and unvaccinated mother were $328.45 and $341.02 respectively, resulting in an expected net benefit of $12.57 per vaccinated mother. The overall savings in the cohort were predicted to range from $3.69 to $14.75 million, depending on the vaccination coverage rate. This strategy would be cost-beneficial, holding all other variables to the base case, if the annual maternal influenza attack rate is more than 2.8%, influenza vaccine efficacy is more than 47%, or if vaccine acquisition and administration cost per dose are less than $32.78. The strategy would not generate net savings from the third-party perspective. Sensitivity analyses were robust, but disease incidence and vaccine efficacy were important drivers.
CONCLUSION:
: Our model suggests that postpartum influenza vaccination is a cost-beneficial approach for prevention of maternal and infantile influenza from a societal perspective.
LEVEL OF EVIDENCE:
: III.
PMID:
22270282
[PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/22270282